Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider John Nuss Sells 13,161 Shares

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 13,161 shares of the stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $2.26, for a total transaction of $29,743.86. Following the completion of the sale, the insider now owns 485,701 shares of the company’s stock, valued at approximately $1,097,684.26. This represents a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ventyx Biosciences Stock Performance

NASDAQ:VTYX traded down $0.02 during trading hours on Thursday, reaching $2.28. The stock had a trading volume of 1,760,269 shares, compared to its average volume of 2,039,973. The stock has a market cap of $161.22 million, a P/E ratio of -0.97 and a beta of 0.48. The stock has a 50 day simple moving average of $2.30 and a 200 day simple moving average of $2.40. Ventyx Biosciences, Inc. has a 12-month low of $1.67 and a 12-month high of $11.48.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on VTYX. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Institutional Investors Weigh In On Ventyx Biosciences

Several large investors have recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC bought a new position in Ventyx Biosciences during the third quarter worth about $26,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Ventyx Biosciences by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after acquiring an additional 5,310 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Ventyx Biosciences in the second quarter worth $32,000. Intech Investment Management LLC purchased a new position in shares of Ventyx Biosciences in the third quarter valued at $42,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after purchasing an additional 7,096 shares during the period. Hedge funds and other institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.